New diabetes shot shows promise in major trial for better sugar and weight control
NCT ID NCT06778967
First seen Jan 05, 2026 · Last updated Jun 11, 2026 · Updated 25 times
Summary
This study tests a new injectable medicine called GZR18 in about 1,100 Chinese adults with type 2 diabetes whose blood sugar is not well controlled by current pills. The goal is to see if GZR18 can lower blood sugar and help with weight loss compared to standard treatments. Participants will receive either GZR18 or an active comparator, and researchers will monitor changes in blood sugar levels and safety over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University General Hospital
Tianjin, China
Conditions
Explore the condition pages connected to this study.